Pune, July 12, 2024 (GLOBE NEWSWIRE) -- The good news is that breakthroughs in medical technology and pharmaceutical research have led to great strides forward concerning novel treatments for diabetic neuropathy. Secondly, the National Institutes of Health (NIH) said some newer treatments are powerful enough to cut neuropathic pain in half. There is also a 30% increase in patient adherence to these advanced therapies over traditional treatments, the CDC adds.
By doing so, these advances not only increase the effectiveness of interventions but also contribute to better health outcomes for patients creating a probable market extension by 7.5% per year according to research from the U.S.
Dept of Health and Human Services. Further, rising government awareness campaigns related to diabetic neuropathy and its management such as the initiatives of the Centers for Disease Control (CDC) and National Institute of Health (NIH), contribute significantly towards market growth due to increasing demand from healthcare professionals & patients. These efforts have resulted in a 25% increase in early diagnosis and a 20% increase in timely intervention, the CDC said.
The increasing prevalence of type 1 & type 2 diabetes, the growing aging population, and the introduction of advanced medical therapies for treatment are expected to present this market with lucrative growth opportunities as a result of expanding at the CAGR over the forecast period suggested by HHS. Nonsteroidal maintained the lar.